These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 3058042)

  • 41. Survival outcome of combined GnRH agonist and tamoxifen is comparable to that of sequential adriamycin and cyclophosphamide chemotherapy plus tamoxifen in premenopausal patients with early breast cancer.
    Sa-Nguanraksa D; Krisorakun T; Pongthong W; O-Charoenrat P
    Mol Clin Oncol; 2019 Nov; 11(5):517-522. PubMed ID: 31620283
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of adjuvant endocrine therapy in primary breast cancer.
    Baum M; Ebbs SR
    Recent Results Cancer Res; 1989; 115():136-43. PubMed ID: 2696026
    [No Abstract]   [Full Text] [Related]  

  • 43. A randomized trial comparing ftorafur alone with ftorafur plus tamoxifen in postoperative adjuvant therapy for breast cancer. Kinki Area Research Group for Postoperative Adjuvant Therapy for Breast Cancer.
    Sakai K; Kosaki G; Seno T; Taguchi T; Terasawa T; Nakao K; Koyama H; Oshima A
    Cancer Chemother Pharmacol; 1996; 37(6):587-92. PubMed ID: 8612314
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee.
    McDonald CC; Stewart HJ
    BMJ; 1991 Aug; 303(6800):435-7. PubMed ID: 1912833
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Adjuvant chemotherapy in breast cancer. Report and commentary on the NIH Consensus Development Conference, Bethesda, Maryland, U.S. 9-11 September, 1985].
    Jakesz R
    Wien Klin Wochenschr; 1985 Nov; 97(21):825-7. PubMed ID: 2865856
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy.
    Friedl A; Jordan VC; Pollak M
    Eur J Cancer; 1993; 29A(10):1368-72. PubMed ID: 8398260
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adjuvant therapy for breast cancer.
    Kaufmann M
    Curr Opin Oncol; 1991 Dec; 3(6):1019-23. PubMed ID: 1843102
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tamoxifen decreases ovarian toxicity without compromising cancer treatment in a rat model of mammary cancer.
    Nynca A; Swigonska S; Ruszkowska M; Sadowska A; Orlowska K; Molcan T; Myszczynski K; Otrocka-Domagala I; Paździor-Czapula K; Kurowicka B; Petroff BK; Ciereszko RE
    BMC Genomics; 2023 Jun; 24(1):325. PubMed ID: 37312040
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Meta-Analysis of the Second Collaborative Study of Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC) in Patients with Stage II, Estrogen-Receptor-Positive Breast Cancer.
    Yoshida M; Abe O; Uchino J; Kikuchi K; Abe R; Enomoto K; Tominaga T; Fukami A; Sugimachi K; Nomura Y; Hattori T; Ogawa N
    Breast Cancer; 1997 Jul; 4(2):93-101. PubMed ID: 11091583
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The Role of Chemoendocrine Agents in Postoperative Adjuvant Therapy for Breast Cancer: Meta-analysis of the First Collaborative Studies of Postoperative Adjuvant Chemoendocrine Therapy for Breast Cancer (ACETBC).
    Abe O
    Breast Cancer; 1994 Jul; P(P):P-P9. PubMed ID: 11091512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Systemic adjuvant chemo-endocrine therapy after breast conservation treatment for breast cancer].
    Miura S; Murai H; Yoshida M
    Rinsho Byori; 1993 Oct; 41(10):1125-32. PubMed ID: 8254958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [The role of adjuvant endocrine therapy in the management of operable breast cancer].
    Miura S; Yoshida M; Murai H
    Gan To Kagaku Ryoho; 1988 Dec; 15(12):3203-13. PubMed ID: 3058042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Direct comparisons of adjuvant endocrine therapy, chemotherapy, and chemoendocrine therapy for operable breast cancer patients stratified by estrogen receptor and menopausal status.
    Nomura Y; Shirouzu M; Takayama T
    Breast Cancer Res Treat; 1998 May; 49(1):51-60. PubMed ID: 9694611
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [A randomized study of adjuvant treatments for operable breast cancer patients stratified by estrogen receptor and menopausal status].
    Nomura Y; Tsutsui S; Murakami S; Takenaka Y
    Gan To Kagaku Ryoho; 1999 Apr; 26(5):643-9. PubMed ID: 10234295
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
    Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
    [TBL] [Abstract][Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.